Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Kazia Therapeutics acquires QIMR Berghofer's epigenetic drug discovery platform and lead candidate for $1.4M upfront
Licensing deal, oncology, AI/ML, drug discovery, small molecule, epigenetics - Read more

Sandoz signs manufacturing and supply agreement with Rwanda government to provide critical medicines across Africa
Manufacturing agreement, infectious disease, oncology, small molecule, commercialization - Read more

PrecisionLife, Ovation.io partner to commercialize GLP-1 predictive genomics stratification tests
Research collaboration, AI/ML, diagnostics, data analytics, commercialization, metabolic disease - Read more

Boehringer Ingelheim, Zai Lab collaborate on dual DLL3-targeting T-cell engager and ADC combination for SCLC
Clinical collaboration, Oncology, Antibody-drug conjugate, T-cell engager, Small cell lung cancer - Read more

Daiichi Sankyo sells consumer health unit Daiichi Sankyo Healthcare to Suntory Holdings for $1.55B
Acquisition, oncology, commercialization, antibody-drug conjugate, consumer health divestiture - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Beeline Medicines debuts with $300M Series A, licensing five Bristol Myers immune disease drug candidates
Small molecule, autoimmune, strategic, major transaction - Read more

Spain plans $200M VC fund bridging Spanish biotechs with Boston's life science ecosystem
Venture capital, life sciences, biotech investment - Read more

Terremoto Biosciences raises $108M Series C to develop AKT-targeting cancer therapies
Oncology, rare disease, small molecule, clinical-stage - Read more

Revolution Medicines raises $2B offering to fund daraxonrasib pancreatic cancer commercialization
Oncology, small molecule, pancreatic cancer, clinical-stage - Read more

Alloy Therapeutics raises $40M Series E to scale AI-driven biotech infrastructure platform
Antibody discovery, AI/ML platform, CRO, drug discovery, biologics manufacturing, services - Read more

Restore Vision secures JPY 1.3B ($8.2M) Pre-Series B, advancing gene therapies for retinal disorders
Gene therapy, retinal disorders, clinical-stage, rare disease - Read more

Telix Pharmaceuticals prices upsized $600M convertible bonds offering, refinancing existing debt
Oncology, radiopharmaceuticals, clinical-stage, diagnostics - Read more

GSK completes acquisition of 35Pharma gaining HS235 for pulmonary hypertension treatment
Protein-based therapeutic, cardiovascular, strategic, major transaction - Read more

FDA advisory committee to review reinstating seven unapproved peptides previously restricted over safety concerns
Peptide, multiple indications, regulatory, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Replimune cuts 63 jobs after second FDA rejection of melanoma therapy RP1
Oncolytic virus, oncology, operational, cost reduction - Read more

FDA extends review period for Savara's (molgramostim) biologics license application in autoimmune pulmonary alveolar proteinosis
Protein therapy, autoimmune, recombinant protein, pulmonary alveolar proteinosis, GM-CSF, rare respiratory disease - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here